

Edited by

**K.D. Rainsford**

# IBUPROFEN

Discovery, Development  
and Therapeutics

WILEY Blackwell



# **Ibuprofen**



# **Ibuprofen**

Discovery, Development and Therapeutics

EDITED BY

**K.D. RAINSFORD**

Biomedical Research Centre, Sheffield Hallam University, UK

**WILEY** Blackwell

This edition first published 2015 © 2015 by John Wiley & Sons, Ltd

*Registered Office*

John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial Offices*

9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell).

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author(s) have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. It is sold on the understanding that the publisher is not engaged in rendering professional services and neither the publisher nor the author shall be liable for damages arising herefrom. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

*Library of Congress Cataloging-in-Publication Data*

Ibuprofen (2015)

Ibuprofen : discovery, development and therapeutics / edited by Kim D Rainsford.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-74338-6 (cloth)

I. Rainsford, K. D., 1941–, editor, contributor. II. Title.

[DNLM: 1. Ibuprofen–pharmacology. 2. Ibuprofen–therapeutic use. QV 95]

RM666.I17

615.7'83–dc23

2015001065

A catalogue record for this book is available from the British Library.

Set in 9/11pt Times by SPi Global, Pondicherry, India

# Contents

<b>List of Contributors</b>	<b>xiii</b>
<b>Preface</b>	<b>xv</b>
<b>1 History and Development of Ibuprofen</b>	<b>1</b>
<i>K.D. Rainsford</i>	
Summary	1
1.1 Introduction	1
1.2 Historical Background	5
1.3 Initial Stages	7
1.4 Compounds in Development	10
1.5 Ibufenac – Almost There, but for Liver Toxicity	12
1.6 More Setbacks	12
1.7 More Learning	12
1.8 Ibuprofen	12
1.8.1 First Clinical Trials	12
1.8.2 Gastrointestinal Safety	14
1.9 Achievements and Rewards at Last	15
1.10 Ultimate Recognition of Safety – OTC Status	17
1.11 Worldwide Developments	19
1.11.1 Evolving Applications of Ibuprofen	19
Acknowledgements	20
References	20
<b>2 The Medicinal Chemistry of Ibuprofen</b>	<b>22</b>
<i>Kenneth J. Nichol and David W. Allen</i>	
2.1 Introduction	22
2.2 The Discovery of Ibuprofen	22
2.3 Synthetic Routes to Ibuprofen	27
2.4 Biological Activities of Ibuprofen Analogues	31
2.5 Metabolites of Ibuprofen	36
2.5.1 Metabolites and Enantiomer Inversion	36
2.5.2 Synthesis of Metabolites	37
2.6 Ibuprofen Enantiomers	38
2.7 Physicochemical Aspects	42
Acknowledgements	43
References	43

<b>3</b>	<b>The Pharmaceutics of Ibuprofen</b>	<b>51</b>
	<i>Fred Higton</i>	
	Summary	51
3.1	Physical and Chemical Characteristics of Ibuprofen	51
3.2	Products Available Worldwide	55
3.3	Solid Dose Presentations	55
3.3.1	Conventional Ibuprofen Tablets	57
3.3.2	<i>In vitro/in vivo</i> Testing	59
3.3.3	Sustained Release Preparations	61
3.3.4	Ibuprofen Fast Acting; Ibuprofen Salts and Derivatives	65
3.4	Liquids	68
3.5	Taste-Masking of Ibuprofen	68
3.6	Suppositories	70
3.7	Topical Presentations	71
3.8	Conclusion	73
	References	73
<b>4</b>	<b>The Pharmacokinetics of Ibuprofen in Humans and Animals</b>	<b>81</b>
	<i>Fakhreddin Jamali and Dion R. Brocks</i>	
	Summary	81
4.1	Absorption	82
4.2	Distribution	83
4.2.1	Protein Binding	83
4.2.2	Tissue Distribution	88
4.3	Clearance	92
4.3.1	Metabolism of Ibuprofen	93
4.3.2	Excretion of Ibuprofen	104
4.4	Interspecies Differences in Pharmacokinetics of ( <i>R</i> )- and ( <i>S</i> )-Ibuprofen	105
4.5	Relationship between Effect and Plasma Concentrations	106
4.5.1	Therapeutic Effects	106
4.5.2	Toxic Effects	107
4.6	Pharmacokinetics in Special Populations	108
4.6.1	Pharmacokinetics and Analgesic Effects in Patients in Pain	108
4.6.2	Febrile Children and Infants	114
4.6.3	Postoperative Paediatric Patients	115
4.6.4	Premature Infants	115
4.6.5	Juvenile Arthritis	116
4.6.6	Children with Cystic Fibrosis	116
4.6.7	Elderly Adults	117
4.6.8	Rheumatic Disease	117
4.6.9	Renal Insufficiency	118
4.6.10	Hepatic Disease	119
4.6.11	Burn Patients	119
4.6.12	Effect of Gender and Race	119
4.6.13	Effect of Operational Stressors	120
4.7	Drug Interactions	120
4.7.1	Anti-ulcer Medications	120
4.7.2	Zidovudine	121
4.7.3	Codeine and Oxycodone	121

4.7.4	Anti-hyperlipidemic Drugs	121
4.7.5	Oral Contraceptive Steroids	122
4.7.6	Self-interaction; Enantiomer–Enantiomer Interaction	123
4.7.7	Effect of Ibuprofen on the Pharmacokinetics of Other Drugs	123
4.7.8	Other Drugs	123
	References	124
<b>5</b>	<b>Pharmacology and Toxicology of Ibuprofen</b>	<b>132</b>
	<i>K.D. Rainsford</i>	
	Summary	132
5.1	Introduction	133
5.2	Basic Pharmacology and Toxicology	134
5.2.1	The Relevance of Data from Animal Models to the Clinical Situation in Humans	134
5.2.2	Acute Anti-inflammatory Activity	136
5.2.3	Chronic Anti-inflammatory Activity	141
5.2.4	Analgesic Activity	143
5.2.5	Antipyretic Activity	149
5.2.6	General Toxicology	149
5.2.7	Effects on Prostaglandin Production Related to Pharmacological Activities	164
5.2.8	Effects on Leukotriene Production	180
5.2.9	Smooth Muscle Contractility	181
5.2.10	Effects on Nitric Oxide Production	181
5.2.11	Leucocytes and Vascular Permeability	182
5.2.12	Leukocyte Functions	188
5.2.13	Immune Functions	191
5.2.14	Effects on Articular Joint Integrity	192
5.2.15	Miscellaneous Biochemical and Cellular Actions	194
5.3	Experimental Therapeutics	196
5.3.1	Endotoxin Shock	196
5.3.2	Acute Lung Injury Induced by Exposure to Chemicals	198
5.3.3	Acute Myocardial Injury and Coronary Functions	199
5.3.4	Cerebral Injury	201
5.3.5	Tourniquet Shock Ischemia	202
5.3.6	Transcutaneous Hypoxia	202
5.3.7	Cytokines and Surgical Stress	203
5.3.8	Pleurisy from Delayed Hypersensitivity Reaction	203
5.3.9	Abdominal Adhesions	203
5.3.10	Uveitis	204
5.4	Clinical Pharmacology and Toxicology	204
5.4.1	Experimental Inflammation	204
5.4.2	Experimental Pain	205
5.4.3	Effects on Platelet Aggregation and Thrombosis	206
5.4.4	Gastrointestinal Injury and Bleeding	208
5.4.5	Hypersensitivity and Other Immunological Reactions	210
5.4.6	Gynaecological and Obstetric Uses	211
5.4.7	Effects on Lung Inflammation in Cystic Fibrosis	212
5.4.8	Malignant Conditions	212
5.4.9	Prevention of Cataract	213
5.5	Conclusions	214
	References	214

<b>6 Therapeutics of Ibuprofen in Rheumatic and Other Chronic and Painful Diseases</b>	<b>237</b>
<i>Walter F. Kean, K.D. Rainsford and the late W. Watson Buchanan</i>	
Summary	237
6.1 Introduction	238
6.2 Overview of Clinical Pharmacology	239
6.2.1 Pharmacokinetics Relevant to Therapy of Inflammatory Diseases and Pain	240
6.2.2 Anti-inflammatory and Analgesic Activities	245
6.2.3 Criteria for Determining Therapeutic Responses	248
6.3 NSAID-Related Adverse Drug Reactions and Toxicity	248
6.3.1 Gastrointestinal Side-Effects	249
6.3.2 Cardiovascular Reactions	253
6.3.3 Hepatic Reactions	253
6.3.4 Renal Adverse Reactions	253
6.3.5 Miscellaneous Reactions	254
6.4 Rheumatoid Arthritis	255
6.4.1 Early Studies at Low Doses	256
6.4.2 Later Higher-Dose Studies	258
6.5 Juvenile Idiopathic (Rheumatoid) Arthritis	262
6.6 Primary and Secondary Osteoarthritis	263
6.6.1 Acceleration of Cartilage and Bone Destruction	272
6.6.2 Therapeutic Aspects	273
6.6.3 Comparisons with Coxibs	273
6.7 Formulations	276
6.8 Variability in Response	276
6.9 Relation of Drug Kinetics to Clinical Response	277
6.10 Low Back Pain	278
6.11 Shoulder Pain	279
6.12 Reactive Arthritis (Reiter's Syndrome)	279
6.13 Psoriatic Arthritis	280
6.14 Ankylosing Spondylitis	280
6.15 Gout	280
6.16 Fibromyalgia	280
6.17 Haemophilic Arthritis	281
6.18 Postoperative Pain	281
6.19 Sports Injuries	281
6.20 Other Painful States	283
6.21 Cancer	283
6.22 Potential Non-analgesic Usage	284
6.23 The Elderly	285
6.24 Dexibuprofen	285
6.25 Conclusions	286
References	287
<b>7 Safety and Efficacy of Non-prescription, Over-the-Counter (OTC) Ibuprofen</b>	<b>313</b>
<i>K.D. Rainsford</i>	
Summary	313
7.1 Introduction	313
7.2 Analysis of Clinical Trials	315
7.2.1 Studies in Prospective Clinical Trials	317

7.3	Epidemiological Studies and Case Reports	327
7.4	Considerations for Special Groups	330
7.4.1	Use of Drugs in the Elderly	330
7.4.2	Safety in Pregnancy and Lactation	331
7.4.3	Uses and Safety in Sport and Exercise	334
7.5	Conclusions	336
	References	336
<b>8</b>	<b>Use of Ibuprofen in Dentistry</b>	<b>346</b>
	<i>Raymond A. Dionne, Sharon M. Gordon and Stephen A. Cooper</i>	
8.1	Introduction	346
8.2	Analgesia	347
8.2.1	Preventive Analgesia	348
8.2.2	Analgesic Activity of Ibuprofen Isomers	349
8.2.3	Ibuprofen-Containing Combinations	350
8.2.4	Ibuprofen Formulations	354
8.3	Effects on Oedema	355
8.4	Interactions with Plasma $\beta$ -Endorphin	356
8.5	Use for Chronic Temporomandibular Pain	356
8.6	Recommendations for the Use of Ibuprofen in Dentistry	358
	References	359
<b>9</b>	<b>Gastrointestinal Adverse Reactions from Ibuprofen</b>	<b>363</b>
	<i>K.D. Rainsford and Ingvar Bjarnason</i>	
	Summary	363
9.1	Background and Introduction	364
9.2	Current Status Concerning NSAID Ulceration	365
9.2.1	Morbidity and Mortality	366
9.3	Occurrence of Ulcers and Complications	369
9.3.1	Epidemiological Studies	369
9.3.2	Large-Scale Mega Trials	376
9.4	Clinical Investigations on Comparative GI Effects of Ibuprofen	378
9.4.1	Early Symptom-Based Studies in GI-Intolerant Subjects	378
9.4.2	Procedures for Assessing GI Injury	379
9.4.3	Upper GI Endoscopy	380
9.4.4	NSAID-Enteropathy: Capsule and Device Assisted Intestinal Endoscopy and Other Techniques	381
9.4.5	Radiochromium [ $^{51}\text{Cr}$ ]-Labelled Red Cell GI Blood Loss	387
9.4.6	Intragastric and Occult Blood Loss and Reduced Haemoglobin	392
9.5	Clinically-Relevant Pathogenesis of NSAID-Associated GI Injury	395
9.5.1	Factors Affecting NSAID-Induced Gastroduodenal Injury	395
9.5.2	Influence of Gastric Acidity	395
9.5.3	Physicochemical Associations, Topical versus Systemic Actions of NSAIDs, Cyclo-oxygenases and Reduced Prostanoids	397
9.5.4	Effects of NSAIDs on Gastric pH and Acid Secretion	400
9.6	Procedures for Reducing GI Symptoms	402
9.6.1	Ibuprofen Formulations	402
9.6.2	Effects of Food or Drinks	404

9.6.3	Mucus Protection Strategies	407
9.6.4	Anti-ulcer Agents	408
9.7	Overall Assessment of GI Safety of Ibuprofen	410
	References	410
<b>10</b>	<b>Hepatorenal Effects of Ibuprofen Compared with other NSAIDs and Paracetamol</b>	<b>430</b>
	<i>K.D. Rainsford</i>	
10.1	Introduction	430
10.2	Hepatorenal Syndromes	431
10.3	NSAID, Analgesic and DMARD-Induced Liver Injury	431
10.3.1	Historical Associations of NSAIDs with Liver Toxicity	431
10.3.2	Awareness of Liver Reactions with Modern NSAIDs	432
10.3.3	Simultaneous Use of Potentially Hepatotoxic Medications	437
10.4	Renal Adverse Reactions Form NSAIDs and Analgesics	440
10.4.1	Renal Adverse Reactions from Ibuprofen	442
10.5	Conclusions	444
	References	444
<b>11</b>	<b>Adverse Drug Reactions Attributed to Ibuprofen: Effects Other Than Gastrointestinal</b>	<b>450</b>
	<i>L.J. Miwa, M. Maneno and Judith K. Jones</i>	
11.1	Introduction	450
11.2	Allergy and Hypersensitivity	451
11.2.1	Points to Consider when Evaluating Allergy-Type Reactions to NSAIDs	451
11.2.2	Epidemiology of Allergy or Hypersensitivity with NSAIDs	452
11.3	Adverse Dermatological Effects	455
11.4	Hepatotoxicity	456
11.5	Haematological Adverse Effects	463
11.5.1	Neutropenia, agranulocytosis and aplastic anaemia	463
11.5.2	Other Blood Disorders	464
11.6	Renal Adverse Effects	464
11.7	Cardiovascular Adverse Effects	468
11.8	Adverse Effects on Reproduction	475
11.8.1	Animal Studies of Teratogenic and Reproductive Effects	475
11.8.2	Reports of Teratogenic Effects in Humans	476
11.8.3	Perinatal Adverse Effects Associated with Therapeutic Use	477
11.8.4	Other Reproductive Effects	478
11.9	Endocrine and Metabolic Adverse Effects	478
11.10	Central Nervous System Effects	478
11.10.1	General CNS Effects	478
11.10.2	Aseptic Meningitis	479
11.10.3	Cognitive Dysfunction	479
11.10.4	Psychiatric Adverse Effects	479
11.11	Ocular Adverse Effects	479
11.12	Infection-Related Adverse Event	480
11.13	Drug Interactions	480
11.13.1	NSAID–Anti-hypertensive Interactions	481
11.13.2	NSAID–Diuretic Interactions	482
11.13.3	NSAID– $\beta$ -Adrenergic Blocker Interactions	482

11.13.4	NSAID–Angiotensin-Converting Enzyme Inhibitor Interactions	482
11.13.5	NSAID–Oral Anti-coagulant Interactions	482
11.13.6	NSAID–Aminoglycoside Interactions	483
11.13.7	NSAID–Oral Hypoglycemic Interactions	483
11.13.8	NSAID–Cyclosporin Interactions	483
11.13.9	NSAID–Lithium Interactions	483
11.13.10	NSAID–Methotrexate Interactions	483
11.13.11	Ibuprofen–Aspirin Interactions	484
11.14	Future Needs	484
	References	485
<b>12</b>	<b>Human Toxicity of Ibuprofen</b>	<b>498</b>
	<i>Glyn Volans</i>	
	Summary	498
12.1	Introduction	498
12.2	Mechanism of Toxicity in Overdosage	499
12.3	Epidemiological Reviews of the Effects of Ibuprofen in Overdosage	499
12.4	Reports of Deaths after Ibuprofen Overdose	500
12.5	Dose–Response and Toxicokinetics	500
12.6	Gastrointestinal Effects	506
12.7	Renal Effects	507
	12.7.1 Cases of Massive Overdose	507
	12.7.2 Cases Affected by Additional Factors	507
12.8	Metabolic Effects	508
12.9	Central Nervous System (CNS) Effects	509
12.10	Cardiovascular Effects	509
12.11	Respiratory Effects	510
12.12	Haematological Effects	510
12.13	Skin Reactions	510
12.14	Ibuprofen Toxicity in Children	510
12.15	Ibuprofen in Pregnancy and Breast Feeding	511
12.16	Chronic Abuse of Ibuprofen	511
12.17	Conclusion	512
	12.17.1 Management of Ibuprofen Overdosage	512
	12.17.2 Continuing Surveillance	513
	12.17.3 Comparative Human Toxicity – Ibuprofen versus Other NSAIDs and Non-opioid Analgesics	514
	References	514
<b>13</b>	<b>Ibuprofen in the Prevention and Therapy of Cancer</b>	<b>518</b>
	<i>Randall E. Harris</i>	
	Summary	518
13.1	Introduction and Background	519
13.2	Ibuprofen, COX-1 and COX-2	520
13.3	COX-2 and the Inflammogenesis of Cancer	520
13.4	Preclinical Efficacy Studies of Ibuprofen and Cancer	521
	13.4.1 Preclinical Efficacy Study of Ibuprofen Therapy for Breast Cancer	521
	13.4.2 Preclinical Efficacy Study of Ibuprofen versus Retinoic Acid for the Prevention of Breast Cancer	521

13.4.3	Preclinical Efficacy Study of Celecoxib versus Ibuprofen for the Prevention of Breast Cancer	522
13.4.4	Other Animal Studies of NSAIDs and Cancer	522
13.5	Human Epidemiologic Studies of Ibuprofen for the Prevention of Cancers of the Breast, Colon, Prostate and Lung	523
13.5.1	Methods of Analysis	524
13.5.2	Comparative Results for Ibuprofen and Aspirin from Eepidemiologic Studies of Cancers of the Breast, Colon, Prostate and Lung	524
13.5.3	Comparison of Ibuprofen, Aspirin and Selective COX-2 Inhibitors in Cancer Prevention	525
13.5.4	Meta-analyses of Epidemiologic Studies of NSAIDs for Cancer Prevention	526
13.5.5	Discussion of Meta-analyses of NSAIDs and Cancer	528
13.6	Therapeutic Studies of Non-selective COX-2 Inhibitors for Human Cancer	529
13.7	COX-2 and the Inflammogenesis of Cancer	531
13.7.1	COX-2 Blockade of Molecular Carcinogenesis	531
13.7.2	Role of COX-1 in Carcinogenesis	532
13.7.3	Other Molecular Targets of NSAIDs	533
13.8	Safety Profile of Ibuprofen	533
13.8.1	COX-1 and COX-2 Isoforms	533
13.8.2	Gastrointestinal and Renal Effects of Ibuprofen	533
13.8.3	Ibuprofen and Cardiovascular Disease	534
13.9	Future Perspectives for Cyclooxygenase Inhibitors in Cancer Chemoprevention	534
	References	535
<b>14</b>	<b>Ibuprofen in Prevention of Neurodegenerative Diseases</b>	<b>547</b>
	<i>K.D. Rainsford</i>	
	Summary	547
14.1	Introduction	548
14.2	Pathogenesis of AD	548
14.3	Early Clinical Observations of Effects of NSAIDs in AD	549
14.4	Cellular and Molecular Effects of Ibuprofen in AD	553
14.4.1	Actions of Ibuprofen in Rodent AD Models	554
14.4.2	<i>In Vitro</i> Effects and Molecular Actions of Ibuprofen in AD	556
14.4.3	Conclusions	557
14.5	Ibuprofen in Parkinson's Disease	557
14.5.1	Effects of Ibuprofen in Models of PD	559
14.6	Other Neuroprotective Effects of Ibuprofen	559
14.7	Conclusions	560
	References	560
<b>Appendix A</b>	<b>Some Proprietary Brands and Preparations of Ibuprofen Available Worldwide</b>	<b>571</b>
	<i>K.D. Rainsford</i>	
<b>Appendix B</b>	<b>References to Analytical Methods for Determination of Ibuprofen in Biological Fluids, Principally Plasma</b>	<b>581</b>
	<i>K.D. Rainsford</i>	
<b>Index</b>		<b>588</b>

# List of Contributors

**Professor K.D. Rainsford, PhD, FRCPEdin, FRCPath, FRSC, FSB, FIBMS, Dr(hc)** Biomedical Research Centre, Sheffield Hallam University, UK

**Professor David W. Allen, DSc** Biomedical Research Centre, Sheffield Hallam University, UK

**Professor Ingvar Bjarnason MD, MSc, FRCPath, FRCP (Glasg), DSc** Department of Gastroenterology, King's College Hospital, UK

**Dr Dion R. Brocks, PhD** Faculty of Pharmacy and Pharmaceutical Sciences, Katz Centre for Pharmacy and Health Research, Canada

**Professor W. Watson Buchanan, MD, FRCP (Glas, Edin, C) (the late)** Sir William Osler Health Institute and McMaster University Faculty of Health Sciences, Canada

**Dr Stephen A. Cooper, DDS, PhD** Palm Beach, USA

**Dr Raymond A. Dionne, DDS, MS, PhD** East Carolina University, Brody School of Medicine, Greenville, NC, USA

**Dr Sharon M. Gordon, DDS, MPH, PhD** School of Dental Medicine, East Carolina University, Greenville, NC, USA

**Professor Randall E. Harris, MD, PhD** Center of Molecular Epidemiology and Environmental Health, Colleges of Medicine and Public Health, Division of Epidemiology and Department of Emergency Medicine, The Ohio State University Medical Center, USA

**Dr Fred Higton, PhD** Higton Associates, UK

**Professor Fakhreddin Jamali,** Faculty of Pharmacy and Pharmaceutical Sciences, Katz Centre for Pharmacy and Health Research, Canada

**Dr Judith K. Jones, MD, PhD** The Degge Group, Drug Safety Research and Information, USA

**Professor Walter F. Kean, MB ChB, MD (Glas), FRCP (Glas, Edin, C)** McMaster University Faculty of Health Sciences, Canada

**Dr M. Maneno** The Degge Group, Drug Safety Research and Information, USA

**Dr L.J. Miwa** The Degge Group, Drug Safety Research and Information, USA

**Dr Kenneth J. Nichol, PhD** Kelso, Scottish Borders, UK

**Dr Glyn Volans, MD, BSc, FRCP** Department of Clinical Pharmacology, School of Medicine at Guy's and St Thomas' Hospitals, UK

# Preface

Now over 50 years since the discovery of ibuprofen at the Boots Company in Nottingham (UK), this drug has evolved to be used in a wide range of conditions. It has now become almost a university standard both for assessment of pain and inflammation as well as therapy of these conditions. This book is intended to be a monograph on all the main aspects of the properties, mechanisms of action and therapeutic uses of ibuprofen. An earlier version of this book was published in 1999 and since then there have been considerable advances in research and clinical studies on ibuprofen. This is reflected in a major increase in original research publications during this period in which ibuprofen has been cited and in which it has been compared with other analgesic or anti-inflammatory drugs or in which its mechanisms and efficacy have been studied. Ibuprofen has also now been used clinically for over 50 years and this is a reflection of its widespread use and acceptance in treating many inflammatory and even non-inflammatory states, many of which are reviewed in this volume.

Without doubt, recognition of the relative safety and efficacy of ibuprofen has come from the large-scale mega-trials undertaken in the past two to three decades on newer cyclo-oxygenase-2 (COX-2) selective or preferential drugs in which ibuprofen, like that of the other 'traditional' NSAIDs (tNSAIDs), diclofenac and naproxen, were used as comparator drugs. To the surprise of many the newer COX-2-selective agents proved no more effective in controlling pain and joint inflammatory symptoms in arthritis or acute pain states than the tNSAIDs. Their serious gastrointestinal (GI) adverse events were lower than some tNSAIDs after short-term use at high anti-inflammatory doses but after long-term use (several months) these advantages were lost or less apparent. Moreover, in arthritic patients taking COX-2 selective agents who needed aspirin for cardioprotection the incidence and severity of serious GI reactions became more frequent, so there were no benefits of the COX-2 selective agents compared with tNSAIDs. The added costs of the COX-2 selective inhibitors also outweighed their benefits.

A surprising outcome from the mega-studies of the coxibs was a marked increase in their incidence of myocardial infarction, stroke and rates of death in patients taking these drugs long-term, with a trend evident that these serious cardiovascular (CV) events were more frequent with coxibs than naproxen or ibuprofen; the situation with diclofenac has become less clear in that this drug appears to have a high incidence of CV events.

The serious or severe GI and CV reactions seen with high long-term so-called 'anti-arthritis' doses of coxibs and some tNSAIDs is not evident, or is indeed rare, with short-term non-prescription or over-the-counter (OTC) sale of drugs such as ibuprofen, ketoprofen or naproxen. With ibuprofen it has now become recognized that this is probably amongst the safest of OTC analgesics (including paracetamol (acetaminophen)). Upper GI bleeding and ulceration seen often with aspirin and high-dose tNSAIDs is of relatively low frequency with ibuprofen and is probably comparable with paracetamol, which is less ulcerogenic than tNSAIDs. Evidence in support of the OTC safety of ibuprofen in both adults and children has come from many studies that have appeared in recent years. These studies along with extensive pharmaco-epidemiological data have given confidence for the safe use of short-term dosages of ibuprofen, while at the same time giving insight to the factors underlying the development of side-effects, e.g. GI upsets and asthma in children, of all OTC analgesics including ibuprofen.

Understanding of the molecular and cellular actions of ibuprofen has given a broader view of its mechanisms of analgesia and anti-inflammatory activities. Hitherto, the prostaglandin (PG) era in the 1970s and 1980s had led to focused views that ibuprofen was a weak PG synthesis inhibitor and that the actions in

controlling inflammation were attributed to one of the two isometric components (the *S*(+) enantiomer) of the drug. While this is well-recognized and now been found with low OTC doses of ibuprofen it is now becoming recognized that stimulating effects on the production in the brain of endocannabinoids, noradrenergic (nor-epinephrine and 5-hydroxy-tryptamine (serotonergic)) pathways contribute to the central nervous system components of analgesia by ibuprofen, and may also be evident with some other analgesics as well.

Moreover, insight into the molecular and cellular processes affected by ibuprofen on cell inflammation and immunological processes affected in chronic inflammation have diversified understanding of the actions of ibuprofen in these inflammatory states. Observations that these actions may contribute to a lower incidence or severity in elderly patients of Alzheimer's disease or other forms of nerve injury have given rise to the view that long-term, even low OTC, doses of ibuprofen may have wider benefits than just control of pain and inflammation. Perhaps these neurological actions could be considered as 'collateral' benefits, especially in elderly arthritic patients or those requiring ibuprofen for various musculoskeletal painful conditions. While these are interesting observations with possible benefits, more research is needed to gain insight into the mechanisms of action in these neurological conditions as well as answering very important questions on the relative benefits and safety of the drug arising from considerations of when the drug should be taken, at what dose and for how long in different neuro-inflammatory states.

The future may be bright for ibuprofen but there are very important developments required for making this relatively safe drug much safer and defining the conditions and uses of the drug in all populations.

My interest in knowledge about ibuprofen has come with my research into the comparative aspects of the pharmacological and therapeutic properties of the non-steroidal anti-inflammatory drugs. This is an exciting area of research and one that is constantly changing, thanks to advances in the understanding of these drugs and their complexities, both from advances in their therapeutic and adverse reactions. Ibuprofen has been at the centre of these advances owing to its long-standing position in the field of pain and inflammation. Emphasis on the pharmacology, therapeutics and adverse reactions in this book has been from a comparative viewpoint so that the reader will be able to appreciate how this drug fits in with the large number of other NSAIDs and analgesics that are available today.

The publication of this book would not have been possible without the enthusiasm, support and efforts of colleagues who have contributed chapters in their specialist areas. Also of immense help have been the valuable discussions I have had with many collaborators over the years, amongst them Professor Walter Kean (McMaster University, Hamilton, Ontario, Canada), Dr Brian Callingham (University of Cambridge, Cambridge, UK), Professor Michael Whitehouse (Griffith University and University of Queensland, Nathan Campus, Brisbane, Queensland, Australia), Professor Ingvar Bjarnason (King's College Hospital, London, UK), Professor Laurie Prescott (University of Edinburgh, Scotland, UK), Emeritus Professor Richard Hunt (McMaster University, Canada, and Radcliff Hospital Oxford, UK), Professor David Haynes and Dr Mel Cantley (University of Adelaide, Adelaide, South Australia, Australia), Professors Audrejs Skesters and Maije Eglite, Dr Tija Zvagule and colleagues (Riga Stradins University and Institute of Occupational and Environmental Health, Paul Stradins Hospital, Riga, Latvia), Professor Stewart Adams OBE (formerly of Boots, Nottingham Research, Nottingham, UK) as well as colleagues in the pharmaceutical industry (amongst them Reckitt Benckiser, Wyeth, Oxford Pharmasciences, PLxPharma) and other companies who have given valuable advice and insight over the years into pharmaceutical developments associated with ibuprofen.

My special thanks to Mrs Veronica Rainsford-Koechli, Mr Alexander Rainsford and Mr William Rainsford who have provided valuable help in the preparation of the text, figures and tables in this book. I would like to record the valuable advice, editorial assistance and most valuable help in preparation of this book of Mss Nicky McGirr, Celia Carden, Fiona Seymour and their colleagues at John Wiley & Sons, Ltd (Chichester, UK).

This book is dedicated to the discoverers of ibuprofen, Dr (later Professor) Stewart Adams and his colleagues at the Boots Company (Nottingham, UK), the late Professor Watson Buchanan (McMaster University, Hamilton, Ontario, Canada) who inspired and supported many including myself.

**Kim Drummond Rainsford**

Sheffield (UK)

February 2014

## **Addendum**

The book which I edited and part-authored on *Ibuprofen. A Critical Bibliographic Review* that was published by Taylor & Francis (CRC) in 1999 has formed a basis in part to some chapters in this book. I am grateful to Taylor & Francis for assigning copyright of the first book on ibuprofen to this one.



# 1

## History and Development of Ibuprofen

K.D. Rainsford


*Biomedical Research Centre, Sheffield Hallam University, UK*

### Summary

Ibuprofen was discovered over half a century ago following pioneering approaches by Professor Stuart Adams OBE for the identification of anti-inflammatory properties of drugs related to aspirin and later screening of a range of acidic compounds that were synthesized by the late Dr John Nicholson. The subsequent clinical assessments of the anti-rheumatic activities of ibuprofen were initially as a prescription-only medication for treating rheumatoid arthritis. With extensive trials in various other rheumatic and painful states the drug consistently proved to be effective and relatively safe. By the early 1980s the data amassed on the safety of ibuprofen set the basis for granting by the health authorities in the United Kingdom and United States of America as a non-prescription drug for over-the-counter (OTC) sale by pharmacies at the half-prescription (1200 mg/day) dose for short-term use by the lay public. Later OTC sale was approved by a large number of drug regulatory agencies worldwide and this has since been extended to it being available in stores under the general sales list (GSL) regulations in a large number of countries. Ibuprofen has become amongst the most widely used pain-relieving medication worldwide with its proven safety and efficacy. The drug has also been widely investigated for application in a variety of painful and non-pain inflammatory states including cancer, Parkinson's disease and dementias, reflecting the unique and novel properties of the drug that would never have been foreseen from knowledge of the properties when it was initially discovered.

### 1.1 Introduction

The history of ibuprofen began over 50 years ago and has been inextricably linked to understanding of the concepts of the pathogenesis of inflammatory diseases and the actions of therapeutic agents used at that time (Rainsford, 2011). The principal initiator of this research leading to the discovery of ibuprofen was



**Figure 1.1** A photograph of Dr Stewart Adams taken in 1987 (a) and a recent photograph taken in 2012 (b).

Dr Stewart Adams (Figure 1.1), a pharmacologist in the Research Department of The Boots Pure Drug Company Ltd at Nottingham, United Kingdom. His aim was to find analgesic drugs with improved efficacy over aspirin. As with all major discoveries, there is an important personal element and what has been attempted here is to bring together information to show what were the most significant events and thoughts that were important for the discovery process. I am most indebted to Stewart Adams for a considerable amount of information and historical detail that enabled me to write this important chapter. I am also especially grateful to him for discussing what have been most interesting historical details and for giving me an insight into those earlier years and the thinking behind the discovery of ibuprofen.


Stewart Adams has written a detailed account of the pharmacological aspects of the discovery of the propionic acids (Adams, 1992). It is worth noting that the discovery of ibuprofen occurred in the period before the discovery by Vane and colleagues in 1971–1973 of prostaglandins as targets for the anti-inflammatory actions of non-steroidal anti-inflammatory drugs NSAIDs (Vane, 1971; Flower et al., 1972; Ferreira, Moncada and Vane, 1973; Moncada, Ferreira and Vane, 1973). Thus there was no biochemical or cellular target established that could have been employed in the identification of anti-inflammatory actions of ibuprofen and its precursors. The animal models that were employed in the discovery of propionic acids and other NSAIDs were the only means then available for identifying their anti-inflammatory activity. The late Dr John Nicholson (Figure 1.2), who first synthesized ibuprofen, reviewed in depth the medicinal chemistry of the propionic acids and the chemical discovery process underlying the development of ibuprofen (Nicholson, 1982). It is not proposed to give a total account of what these expert authors have already reviewed in depth. I hope more to emphasize the main thinking at the time and key events involved in the discovery of what has been one of the most successful NSAIDs developed since aspirin.

The standard drugs for treating rheumatoid arthritis and other painful arthritic diseases at the time when Stewart Adams started his research were aspirin and cortisone. The pioneering studies supported by the


Empire Rheumatism Council (later to become the Arthritis and Rheumatism Council) and the Medical Research Council in the United Kingdom had established the efficacy of cortisone and aspirin in the relief of pain and soft-tissue swelling in rheumatoid arthritis. However, the shortcomings of both drugs were becoming strikingly evident even at the time of these reports.

In the 1950s when Boots were beginning this research, only a few other companies had begun research programmes into aspirin-type drugs, notably Dr T.Y. Shen at Merck and Company (Rahway, NJ, USA) and Dr Steve Winder at Parke Davis (Ann Arbor, MI, USA). Before this Dr G. Wilhelmi at J R Geigy AG (Basel, Switzerland) had worked on derivatives of amidopyrine and other pyrazoles. In 1958 Winder and his colleagues published an important paper indicating their thinking about the use of the ultraviolet (UV) erythema technique for determining the anti-inflammatory activity of novel compounds. This assay was similar to that in use at Boots and they had, moreover, obtained similar results with standard drugs (e.g. aspirin). The Parke Davis group eventually produced mefenamic acid, flufenamic acid and other fenamates as a result of the initial testing of compounds in this assay.


Boots, however, started with a distinct disadvantage with their meagre resources as their Pharmacology Department was housed in a group of old rambling buildings attached to a Victorian house located in the outskirts of Nottingham (Figures 1.3 to 1.5). It was moved there at the beginning of the Second World War from the centre of Nottingham as a precaution against bombing – a wise move since part of the Research Department was destroyed in an air raid in 1941. The first six years of the research on new aspirin-type drugs was thus carried out under most unsatisfactory conditions. Adams' laboratory (Figure 1.3) was in one of the 'front rooms' of the house and later he was able to acquire the kitchen and larder (Figure 1.4) as additional accommodation.



**Figure 1.2** The 'ibuprofen team' comprising Stewart Adams (centre) with his technician, Colin Burrows (right) and John Nicholson (left).



**Figure 1.3** Stewart Adams with John Nicholson, Colin Burrows (right) in the mid-1960s.



**Figure 1.4** Part of the laboratory ('kitchen') in 1957 showing the Kromayer ultraviolet lamp in the background and guinea-pig holding cages on either side.



**Figure 1.5** The house where Stewart Adams had his laboratory in Rutland Road, West Bridgford, Nottingham and where the early pharmacological studies leading to the discovery of ibuprofen were performed.

## 1.2 Historical Background

It has been said that the road to drug development is a minefield, the path through which is both tortuous and dangerous. One of the leading medicinal chemists in the field of inflammatory drug research, T.Y. Shen, who developed the NSAIDs indomethacin, sulindac and diflunisal at Merck and Company (USA), described the period, 1955–1970, during which the earlier NSAIDs such as ibuprofen and indomethacin were developed as the ‘golden era’ of Edisonian empiricism (Shen, 1984). Without doubt this era set the stage for the later proliferation of NSAIDs in the 1970s and 1980s, many of which were discovered serendipitously (Shen, 1984) and are considered by some to represent little advance over those drugs developed previously. The mechanisms underlying the development of the rheumatic diseases for which these drugs were intended were little understood. The drugs available for treating pain and inflammation in rheumatic diseases in the 1950s to 1960s included aspirin, the other salicylates, aminophenols (phenacetin) and pyrazolones, which dated from the beginning of the century; phenylbutazone (which was originally used to solubilize aminopyrine and accidentally discovered as an effective anti-inflammatory drug); and the corticosteroids discovered in the 1950s (Shen, 1984). Gold salts had also been found in the 1930s to have disease-modifying activity in rheumatoid and related arthropathies, though in the 1950s they were regarded as very toxic.

Thus, with the current remedies for rheumatic diseases being aspirin, corticosteroids, phenylbutazone and, to a lesser extent, gold salts, the need was readily identified in the 1950s for a more potent drug than aspirin, one that would not produce the potentially fatal side-effect of agranulocytosis seen with phenylbutazone or the serious side-effects with corticosteroids. Indeed a report (No. 848 entitled ‘The Testing of

## 6 *Ibuprofen: Discovery, Development and Therapeutics*

Non-hormonal Anti-rheumatic Compounds' by Adams from the Pharmacology and Physiology Division of the Research Department at the Boots Pure Drug Company) dated 5 March 1956 and prepared by Dr Adams noted:

Apart from cortisone and related steroids, aspirin and phenylbutazone are the only two drugs which are universally used to bring about relief of pain and increased mobility in rheumatoid arthritis. Aspirin, because it is a very safe drug, is usually preferred.

Also,

From discussions with Dr Duthie [a leading rheumatologist of the time] at Edinburgh [Northern General Hospital], Dr Bywaters [also a leading rheumatologist] at Taplow and Dr Hill at Stoke Mandeville, it is obvious that aspirin and phenylbutazone are the only established non-hormonal compounds in the treatment of rheumatoid arthritis, while aspirin and sodium salicylate are very effective in the treatment of rheumatic fever.

Furthermore,

We believe that virtually no attempt has been made to investigate thoroughly the anti-inflammatory properties of salicylate-type anti-rheumatics. In view of the widespread use of aspirin and sodium salicylate over the past 50 years this seems to be an amazing omission.

The key to the need to develop a drug that would be superior to aspirin, less toxic than phenylbutazone and without the hormonal associations and side-effects associated with cortisone derives from the following quotes in Dr Adams' report:

We recently discussed our results [from guinea-pig UV erythema assays with benzoic/salicylic acids and related compounds], with Dr Duthie of the Rheumatism Research Unit, Edinburgh, and he was strongly in favour of the type of investigation [involving the development of a drug to replace existing agents] which is envisaged here. Dr Duthie who is a staunch supporter of aspirin and opposed to cortisone, believes that a 'super' aspirin or non-toxic phenylbutazone would have an immense market.

Moreover:

The main disadvantage of the compounds of this type [pyrazoles] which have been used clinically, e.g. phenazone, amidopyrine, and phenylbutazone, is that prolonged administration of therapeutic doses may give rise to toxic side-effects including agranulocytosis. This we believe is the main objection to the further investigation of compounds of this nature.

It is important to note that at this stage Adams believed that the analgesic action of aspirin could be explained entirely on its anti-inflammatory properties – a hypothesis that despite some subsequent qualification has proved at least partly valid. This report by Dr Adams is interesting from the insight that it gives to the thinking about anti-rheumatic therapies at the time and the potential for commercial developments. This report was important because it made a plea for chemical support at Boots to enable development of new anti-rheumatic drugs. This plea proved successful as ultimately this chemical development led to the discovery of ibuprofen and so this report represented a major milestone in the development of the drug.


An interesting aspect concerning the use of aspirin and ideas about developing a 'super' aspirin is that no mention was made in the report of the gastrointestinal side-effects of aspirin that were discussed in the literature at the time. The gastrointestinal side-effects of aspirin were recognized by many rheumatologists at that time. Although not mentioned in report No. 848, it was an aim of Adams' group to produce a compound that would be 'well tolerated by the gastrointestinal tract'. Extensive studies were carried out to find those compounds with the best potential in this respect. Over the years this was always a major target in the studies by the group and it is not entirely good luck that ibuprofen is now considered to be the safest of the NSAIDs.

### 1.3 Initial Stages

This report by Dr Adams in 1956 was making the case for development of a programme for 'non-hormonal' anti-rheumatic compounds; at this time the 'project' team was merely Adams and one technician. Adams and Colin Burrows had already modified the UV erythema assay in guinea-pigs first described by Wilhelmi (1949), who had used this to identify the anti-inflammatory activity of phenylbutazone (Adams and Cobb, 1958). This was later adapted for the assay of skin erythema in humans using Trafuryl as the inflammogen (Figure 1.6). Adams and Burrows later developed a more sophisticated technique requiring only a 20-second exposure to UV without the need to anaesthetize the animal, a feature that not only removed the confounding effects of anaesthesia but also enabled them to test appreciably more compounds each day. Their technique (Dr S.S. Adams, 1998, Figure 1.4, personal communication) was as follows:

Shaved albino guinea-pigs were dosed orally with aspirin or test compound 30 min before a 20-second exposure to ultraviolet light from a Kromayer lamp. Two hours later the degree of erythema was estimated visually on a scale of 0–4 (maximum=4) by an observer who was unaware of the dosage schedules. The 2 hr erythema could be completely suppressed by oral doses of 160 mg/kg aspirin and this drug was employed as a positive standard in each day's experiments. In fact there was only suppression of the erythema at 2 hr since it became fully developed after 24 hr.

Adams and Cobb, 1963



**Figure 1.6** Application of the Trafuryl erythema assay on the volar surface of the forearm. Left to right: Adams, Nicholson and Cobb.

8 *Ibuprofen: Discovery, Development and Therapeutics*

Using this assay Adams showed that the anti-erythemic activity of compound RB 1472 (later named ibuprofen) was discovered on 19 December 1961 (Figure 1.7). This was quickly followed by filing of a patent, the final specification of which was made on 12 January 1962 (Figure 1.8).

DATE 19.12.61 BATH NO. 271 DOSED 11.30 EXPOSED 12.20 EXAMINED 2.20 P. 2229

Animal.	Wt.	Vol	RD number	mg/kg	Result		Animal	Wt.	Vol	RD number	mg/kg	Result	
RH	780	3.0	RB 1448	160	2	1	YHT <sup>25</sup>	790	1.44	RP 1	80	1	0
RHT	770	3.08		160	0	2	YHT <sup>26</sup>	650	2.60	RP 1	160	1	1
RHT	710	0.71	Aspirin	40	1	3	GH <sup>27</sup>	650	2.60		160	0	0
RHT	750	1.50	RB 1472	10	0	0	GH <sup>28</sup>	670	2.68	Aspirin	160	0	0
RHT	570	1.14		10	0	0	GH <sup>29</sup>	710	2.87	RB 1461	20	3	3
RHB	690	2.76	RB 1472	20	0	0	GH <sup>30</sup>	700	1.40	RB 1461	10	4	4
RHB	690	2.76		20	0	0	GH <sup>31</sup>	720	2.88	RB 1461	20	4	4
RHB	620	2.08	Aspirin	160	2	3	GH <sup>32</sup>	630	2.52	RB 1461	20	4	4
RH	760	1.52	Aspirin	80	1	3	GH <sup>33</sup>	670	1.34	RB 1461	40	3	4
RHT	680	1.36	RB 1472	40	1	1	GH <sup>34</sup>	660	1.32		40	1	3
RHT	620	1.24		40	0	0	GH <sup>35</sup>	600	1.96	RB 1461	80	1	1
RHT	790	3.16	RB 1472	80	2	1	RT <sup>36</sup>	720	2.88		80	2	2
RHT	710	2.84		80	1	0	RT <sup>37</sup>	720	2.72	RB 1461	20	2	4
RHB	760	0.76	Aspirin	40	2	4	YR <sup>38</sup>	760	0.74		20	1	2
RHTB	830	3.32	S 20	240	3	4	YR <sup>39</sup>	820	1.64	RB 1461	40	2	3
RHTB	800	3.20	S 21	240	4	4	RB <sup>40</sup>	750	1.50		40	0	1
RHTB	630	2.52	S 22	80	4	4	RB <sup>41</sup>	630	2.52	RB 1461	80	0	2
RHTB	700	2.80		80	4	4	YR <sup>42</sup>	660	2.64		80	1	0
YH	650	2.60	S 22	240	4	4	GR <sup>43</sup>	710	2.84	13103	80	4	4
YHT	780	3.12	S 23	240	3	4	RTB <sup>44</sup>	770	3.08	13088	80	3	4
YHT	580	1.16	Aspirin	80	0	3	RTB <sup>45</sup>	580	2.32	13122	40	4	4
YHT	700	0.70	RP 1	40	0	0	YTB <sup>46</sup>	700	2.80	S 11	240	4	4
YHT	750	0.75		40	0	1	YTB <sup>47</sup>	680	2.72	S 13	240	3	4
YHB	630	1.26	RP 1	80	0	0	RTB <sup>48</sup>	600	2.40	S 14	240	4	4
							BTRB	690	2.76	S 15	240	4	4
							BTB	530	2.82	S 16	240	3	4

Figure 1.7 Extracts from the files showing the first testing of ibuprofen on 19 December 1961. Each figure is the degree of redness (on an increasing scale of 0 to 4) for each individual guinea-pig. Ibuprofen was RB 1472, an early temporary number. The two sets of readings represent observations before and after light 'stroking' of the skin in the erythematous area; the 'stroking' appeared to enhance the sensitivity of detection.



## PATENT SPECIFICATION

NO DRAWINGS

971700

Inventors: JOHN STUART NICHOLSON  
and STEWART SANDERS ADAMS

Date of filing Complete Specification: Jan. 12, 1962.

Application Date: Feb. 2, 1961.

No. 3999/61.

Complete Specification Published: Sept. 30, 1964.

© Crown Copyright 1964.

Index at acceptance:—C2 C(2A2, 2A14, 2R15, 2T16, 3A8A2, 3A8B2, 3A8C3, 3A8K, 3A10A4E, 3A10A4F, 3A10A5A1, 3A10A5A2, 3A10A5E, 3A10A5F, 3A10A5G2, 3A10A5K, 3A10B2C, 3A10B5E, 3A10E3C1, 3A10E4A3, 3A10E5D, 3A10E5E, 3A10E5F1A, 3A10E5F1E, 3A10E5F2A, 3A10E5F3A, 3A10E5F3D, 3A13A3A2, 3A13A3A3, 3A13A3B1, 3A13A3F3); A5 B(1S, 2S)

International Classification:—C 07 c (A 61 k)

## COMPLETE SPECIFICATION


## Anti-Inflammatory Agents

We, BOOTS PURE DRUG COMPANY LIMITED, a British Company, of Station Street, Nottingham, England, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to phenylalkane derivatives. More particularly it relates to novel pharmaceutical and veterinary compositions which comprise as the active ingredient one or more members of a specified group of derivatives of toluene. The invention also relates to the provision of novel members of this specified group of compounds.

It is an object of the invention to provide therapeutic compositions for the relief of pain, fever and inflammation in man and animals which do not suffer from the disadvantages of similar therapeutic compositions based on aspirin, phenylbutazone or adrenocorticosteroids.

We have now discovered that compounds of the general formula I



wherein R<sup>1</sup> represents ethyl, propyl, butyl, alkenyl (C<sub>2</sub>—C<sub>4</sub>), pentyl (except n-pentyl), alkoxy (C<sub>1</sub>—C<sub>4</sub>), allyloxy, phenoxy, phenylthio or cycloalkyl (C<sub>3</sub>—C<sub>6</sub>) optionally substituted by methyl or ethyl in the 1-position, R<sup>2</sup> represents hydrogen or methyl and X represents the radical COOH, COOR<sup>3</sup> wherein R<sup>3</sup> represents alkyl (C<sub>1</sub>—C<sub>4</sub>) or optionally N-alkylated aminoalkyl (C<sub>2</sub>—C<sub>4</sub>), COOM wherein M represents the ammonium ion or a single [Price 4s. 6d.]

equivalent of a non-toxic metallic cation, COOH.B wherein B represents a non-toxic organic base, CONH<sub>2</sub>, CH<sub>3</sub>NH<sub>2</sub> or the group CH<sub>2</sub>OR<sup>4</sup> where R<sup>4</sup> represents hydrogen or lower alkanoyl (C<sub>1</sub>—C<sub>4</sub>) have valuable anti-inflammatory, analgesic and antipyretic properties.

Furthermore in general the compounds exhibit low toxicity and low irritancy to the gastric mucosa, they do not have other undesirable pharmacological activities which might give rise to unwanted side effects and they are stable in the presence of water.

According to the present invention there are provided therapeutic compositions comprising as active ingredient one or more compounds of the general formula I in association with a pharmaceutically acceptable diluent or carrier.

The following compounds are typical of the active compounds of the general formula I, but do not limit the invention in any way:—

- 4-n-Propylphenylacetic acid
- 4-Ethoxyphenylacetic acid
- 4-Isopropylphenylacetic acid
- 4-propoxyphenylacetic acid
- 4-Isopropoxyphenylacetic acid
- 4-s-Butylphenylacetic acid
- 4-Allyloxyphenylacetic acid
- 4-t-Butylphenylacetic acid
- 4-Cyclopentylphenylacetic acid
- 4-isobutylphenylacetic acid
- 4-Cycloheptylphenylacetic acid
- 4-Cyclohexylphenylacetic acid
- 4-(1-Ethylpropyl)phenylacetic acid
- 4-Phenoxyphenylacetic acid
- 4-(1,2-dimethylpropyl)phenylacetic acid
- 4-Phenylthiophenylacetic acid
- α-(4-Cyclohexylphenyl)propionic acid

Figure 1.8 The Patent Specification for the UK Patent No. 971,700 covering the therapeutic compositions of phenylalkanoic acid derivatives, including ibuprofen, for the relief of pain, fever and inflammation that were developed by Dr John Nicholson and Dr Stewart Adams. The filing of the complete specification was on 12 January 1962.

One of the factors that was important in the decision to proceed with the use of the erythema technique was the fact that corticosteroids were inactive. Thus the actions of aspirin-type drugs in this assay could be regarded as specific to this class of compounds. Later pioneering studies both of Collier (1963) on the 'antagonism' of kinins by aspirin, phenylbutazone, mefenamic acid and other compounds, and of Vane (Vane, 1971; Flower et al., 1972; Moncada, Ferreira and Vane, 1973) showing that the anti-inflammatory, analgesic and antipyretic effects of aspirin and related compounds are related to their effects on the production of prostaglandins were important in understanding the actions of these NSAIDs. However, it is important to note that the discovery of ibuprofen and other NSAIDs did not proceed with the advantage of knowing how aspirin-type drugs worked.

Adams and his colleagues had assayed the anti-erythemic activity of a number of salicylates that had been proposed or shown to have anti-inflammatory or pain-relieving effects in rheumatic patients, including the hydroxylated metabolites of salicylate, most of which had proved to have low or nonexistent activity. These results on the development of salicylates and other NSAID derivatives at that time have been discussed in an extensive review by Adams and Cobb (1967) and also by Rainsford (1984). The stage was therefore set for developing a 'super' aspirin. The UV erythema assay had been validated and, in general, a number of salicylates/benzoates tested, most of which had been found to also have comparable (in)activity in patients (Adams and Cobb, 1967).

## 1.4 Compounds in Development

The case for chemical support set out in the report (No. 848) by Dr Adams was successful and the late Dr John Nicholson, an organic chemist (see later), joined Adams and a testing programme was commenced using the guinea-pig UV erythema.

It was clear from report No. 848 that the first compounds to be made would be salicylates and phthalates. There was great optimism, since such compounds had never been investigated before, that agents more potent than aspirin would emerge. This proved to be so, but sadly they were always more toxic than aspirin. This line of attack was therefore abandoned, but the studies proved invaluable since they indicated the importance of the carboxylic group of aspirin for anti-inflammatory activity. It was therefore decided to examine a range of simple compounds with carboxylic acid moieties. Among these a number of phenoxyalkanoic acids were found to be more active than aspirin in inhibiting the UV erythema. This group of compounds were originally made by Boots as herbicides and were available in the files at that company (Nicholson, 1982).

It is fascinating to note that two plant growth regulators – an indolylacetic acid and a phenoxyalkanoic acid – were the lead compounds at both Merck and Boots. These eventually led to the development of indomethacin and ibuprofen respectively (Shen, 1971; Nicholson, 1982).

John Nicholson was the chemist who led the team involved in the synthesis of the phenoxy compounds and the other progenitors of ibuprofen. After the screening of over 600 phenoxyalkanoic acids made by Nicholson and his colleagues, two compounds emerged in 1958 with potential anti-inflammatory activity: BTS 7268 with twice the anti-inflammatory activity of aspirin and BTS 8402, which was 6–10 times more potent (Table 1.1). The ethyl ester of BTS 8402 was prepared on the basis that this might have less gastric intolerance than aspirin but was found inactive in the treatment of rheumatoid arthritis at 1.8 g daily (Nicholson, 1982). As Adams (1987a) queried: 'Did this mean that after seven years our entire programme had been based on a false hypothesis – and if so, what should we do next?'

The turning point came with Adams adopting a newly published American technique for analgesic activity, the Randall–Selitto assay based on the relief of pain from pressure applied to the inflamed paws of rats. Up to this time there was no method of showing an analgesic action of aspirin in animals at reasonable oral doses. Using this technique and an anti-pyretic assay it was discovered that the analgesic activity of BTS 8402 was only comparable with that of aspirin and that its antipyretic activity was even lower (Table 1.1).